Key Developments: BioMarin Pharmaceutical Inc (BMRN.O)
64.01USD
17 May 2013
$-0.49 (-0.76%)
$64.50
$64.58
$65.30
$63.30
1,459,698
1,304,301
$71.56
$34.30
Latest Key Developments (Source: Significant Developments)
Biomarin Pharmaceutical Inc Reaffirms FY 2013 Guidance
Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects total revenue of $530 to $555 million, GAAP net loss of $(195) to $(170) million and non-GAAP adjusted EBITDA (loss) $(75) to $(50) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $550 million for fiscal 2013. Full Article
Biomarin Pharmaceutical Inc Issues FY 2013 Guidance; Revenue And Net Income Guidance Below Analysts' Estimates
Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects total revenue of $530 to $555 million, GAAP net loss of $(195) to $(170) million and non-GAAP adjusted EBITDA (loss) $(75) to $(50) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $563 million, net income of ($115) million and EBITDA of ($68) million for fiscal 2013. Full Article
Biomarin Pharmaceutical Inc Will Not Sell Itself For 25%-30% Premium-Reuters
Reuters reported that Biomarin Pharmaceutical Inc would not consider a buy out offer for even a 25%-30% premium, according to the company's chief executive officer. He said any decision to sell would come from large shareholders, not him nor the board. Full Article
Biomarin Pharmaceutical Inc Updates FY 2012 Revenue Guidance-Conference Call
Biomarin Pharmaceutical Inc announced that it expects around $500 million of revenues in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $497 million for fiscal 2012. Full Article
Biomarin Pharmaceutical Inc Acquires Zacharon Pharmaceuticals
Biomarin Pharmaceutical Inc announced that it has acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan and glycolipid metabolism. Under the terms of the stock purchase agreement, BioMarin paid $10 million upfront for 100% of Zacharon's share capital and may make potential additional payments for clinical, regulatory and commercial milestones. Full Article
Biomarin Pharmaceutical Inc Reaffirms FY 2012 Guidance-Conference Call
Biomarin Pharmaceutical Inc announced that for fiscal 2012, it expects total revenue in the range of $ $475-$510 million and Non-GAAP Adjusted EBITDA in the range of $(5)-$5 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $499 million for fiscal 2012. Full Article
Biomarin Pharmaceutical Inc Reaffirms FY 2012 Revenue And EBITDA Guidance; Raises FY 2012 Net Income Guidance
Biomarin Pharmaceutical Inc announced that for fiscal 2012, it expects total revenue in the range of $ $475-$510 million, GAAP Net (Loss) in the range of $(100)-$(110) million and Non-GAAP Adjusted EBITDA in the range of $(5)-$5 million. The guidance for revenue and Non-GAAP Adjusted EBITDA is unchanged from prior guidance range. Prior guidance for GAAP Net (Loss) was in the range of $(105)-$(115) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $496 million and net income of $(103) million for fiscal 2012. Full Article
Biomarin Pharmaceutical Inc Revises FY 2012 Revenue Guidance To A Range In Line With Analysts' Estimates-Conference Call
Biomarin Pharmaceutical Inc announced that for fiscal 2012, it expects to grow revenues around $500 million. According to I/B/E/S estimates, analysts are expecting the Company to report revenue of $496 million for fiscal 2012. Full Article
Biomarin Pharmaceutical Inc Reaffirms FY 2012 Revenue Guidance-Conference Call
Biomarin Pharmaceutical Inc announced that revenue guidance for fiscal 2012 is $475 million to $510 million topline. From a bottom line, from an operating standpoint at non-GAAP adjusted EBITDAs. Full Article
BioMarin Pharmaceutical, Inc. Reaffirms FY 2012 Revenue Guidance; Lowers FY 2012 Earnings Guidance
BioMarin Pharmaceutical, Inc. announced that for fiscal 2012, it now expects total revenues in the range of $475 million to $510 million, GAAP Net (Loss) in the range of $(115) million to (105) million (prior guidance for fiscal 2012 GAAP Net (Loss) was in the range of $(92) million to $(82) million) and non-GAAP adjusted EBITDA in the range of $(5) million to $5 million (prior guidance for fiscal 2012 non-GAAP adjusted EBITDA was in the range of $15 million to $25 million). According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $495 million and net income of $(85) million for fiscal 2012. Full Article
BioMarin won't sell itself for 25-30 percent premium: CEO
SAN FRANCISCO - BioMarin Pharmaceutical Inc , which makes high-priced drugs used to treat rare diseases, would not consider a buy-out offer for even a 25-30 percent premium, according to the company's chief executive officer.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
